

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM protein - protein search, using sw model

Run on: June 18, 2001, 15:31:56 ; Search time 50.45 Seconds
(without alignments)
242.476 Million cell updates/sec

Title: US-09-653-755A-5
Perfect score: 1121
Sequence: 1 ENVLQSPALMSAPEKVT.....EATHKSTSPIYKSFNRNC 214

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 390729 seqs, 57163235 residues
Total number of hits satisfying chosen parameters: 390729

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :
1: A.Geneseq_0401.*
2: /SIDS6/gcgdata/geneseq/geneseq/AA1980.DAT.*
3: /SIDS6/gcgdata/geneseq/geneseq/AA1981.DAT.*
4: /SIDS6/gcgdata/geneseq/geneseq/AA1982.DAT.*
5: /SIDS6/gcgdata/geneseq/geneseq/AA1983.DAT.*
6: /SIDS6/gcgdata/geneseq/geneseq/AA1984.DAT.*
7: /SIDS6/gcgdata/geneseq/geneseq/AA1985.DAT.*
8: /SIDS6/gcgdata/geneseq/geneseq/AA1986.DAT.*
9: /SIDS6/gcgdata/geneseq/geneseq/AA1987.DAT.*
10: /SIDS6/gcgdata/geneseq/geneseq/AA1988.DAT.*
11: /SIDS6/gcgdata/geneseq/geneseq/AA1989.DAT.*
12: /SIDS6/gcgdata/geneseq/geneseq/AA1990.DAT.*
13: /SIDS6/gcgdata/geneseq/geneseq/AA1991.DAT.*
14: /SIDS6/gcgdata/geneseq/geneseq/AA1992.DAT.*
15: /SIDS6/gcgdata/geneseq/geneseq/AA1993.DAT.*
16: /SIDS6/gcgdata/geneseq/geneseq/AA1994.DAT.*
17: /SIDS6/gcgdata/geneseq/geneseq/AA1995.DAT.*
18: /SIDS6/gcgdata/geneseq/geneseq/AA1996.DAT.*
19: /SIDS6/gcgdata/geneseq/geneseq/AA1997.DAT.*
20: /SIDS6/gcgdata/geneseq/geneseq/AA1998.DAT.*
21: /SIDS6/gcgdata/geneseq/geneseq/AA1999.DAT.*
22: /SIDS6/gcgdata/geneseq/geneseq/AA2000.DAT.*
23: /SIDS6/gcgdata/geneseq/geneseq/AA2001.DAT.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Length	ID	Description
1	1084.5	96.7	215 14 R43674	Mouse anti-bovine
2	1079.5	96.3	215 17 R99644	Anti-bGH monoclonal
3	1078.5	96.2	215 17 R97377	Murine anti-BGH MA
4	1009.5	90.1	235 17 W06178	Murine ASB57 Light
5	1009.5	90.1	235 20 W82746	Plasmid PE814/ASB7
6	1004	89.6	214 17 W15933	Antibody 7G12 light
7	993.5	88.6	213 10 P93035	Chimeric antibody
8	979.5	87.4	235 12 R13060	Monoclonal antibody
9	973.5	86.8	195 11 R06477	Light chain of ant
10	950	84.7	208 20 Y44175	Mab Fab13B5 light
11	911	81.3	238 19 W83042	Anti-Fas Mab HFE7A

12	911	81.3	238 21 B14748	Mouse anti-Fas ant
13	911	81.3	238 21 W90898	Murine anti-Fas an
14	898.5	80.2	219 16 R76086	MAB 55.1 light cha
15	898.5	80.2	239 16 R76087	MAB 55.1 light cha
16	897	80.0	222 18 W01751	MHI monoclonal ant
17	893	79.7	236 20 Y30116	Murine anti-botcul
18	893	79.7	236 20 Y30120	Murine anti-botcul
19	893	79.7	236 20 Y30122	Murine anti-botcul
20	892	79.6	216 17 W15935	Antibody 3G2 light
21	885	78.9	220 15 R53802	FAB light chain to
22	884.5	78.9	219 14 R44495	Sequence of the im
23	883	78.8	214 18 W27089	Mouse monoclonal a
24	882	78.7	218 16 R75457	Mouse antibody FB3
25	882	78.7	218 16 R75459	Mouse antibody FA-
26	882	78.7	234 16 W1518	Mouse antibody FA-
27	877	78.2	223 5 P40031	Murine MAB SK48-E2
28	873	77.9	215 16 R64202	Kappa anti-carcino
29	864.5	77.1	238 18 W31752	Monoclonal antibod
30	864.5	77.1	238 18 W31752	I. chain subunit of
31	864.5	77.1	238 21 B12909	Anti-human Fas mon
32	859.5	76.7	215 15 R53803	FAB light chain to
33	858.5	76.6	219 21 Y95258	Anti-human Fas ant
34	858	76.5	206 20 Y39452	Antibody ABX-CBL 1
35	856.5	76.4	219 15 R59416	6D9 antibody light
36	855.5	76.3	235 15 R47449	784.12 light chain
37	855.5	76.3	235 15 R47451	784.12 L4-12-1 lig
38	853.5	76.1	219 21 Y68994	Amino acid sequenc
39	852.5	76.0	238 20 Y17416	Mouse immunoglobul
40	850	75.8	212 15 R52659	Porphyrin antibody
41	849	75.7	218 16 R75461	Mouse antibody H3-
42	846	75.5	209 16 R64204	Monoclonal antibod
43	843	75.2	215 20 R74781	Light chain of 59.
44	842	75.1	233 20 Y30118	Murine anti-botcul
45	837.5	74.7	239 16 R66757	Anti-tobacco mosai

ALIGNMENTS

RESULT 1	
R43674	R43674 standard; Protein; 215 AA.
AC R43674:	
DT 23-MAY-1994	(first entry)
XX	
DE	Mouse anti-bovine growth hormone MAB light chain.
XX	
DE	Monoclonal antibody; MAB; affinity; binding; antigen; diagnostics;
KW	therapy; imaging; purification; biosensors.
XX	
OS	Mus musculus.
XX	
PN	US5260203-A.
XX	
PD	09-NOV-1993.
XX	
PF	02-SEP-1986; 86US-0902971.
XX	
PR	02-SEP-1986; 86US-0902971.
PR	02-SEP-1987; 87US-0092110.
PR	19-JAN-1989; 89US-0299617.
PR	25-APR-1990; 90US-0512910.
PA	(ENZO-) ENZON INC.
PI	Bird RE, Hardman K, Ladner RC;
XX	
DR	WPI; 1993-367875/46.
DR	N-PSDB; Q51535.
XX	
PT	Single chain poly:peptide for binding antigen - comprising light

PT and heavy chain antigen binding portions linked by peptide linker
XX
PS Disclosure; Figure 22; 78pp; English.

CC This sequence is the mature light chain of a monoclonal antibody
CC (Mab) and is the starting material for the production of a single
CC chain polypeptide having binding affinity for a given antigen
CC (Bovine growth hormone). The polypeptide comprises a first
CC polypeptide comprising the antigen binding portion of of the light
CC chain variable region of an antibody and a second polypeptide
CC comprising the antigen binding portion of the heavy chain variable
CC region of an antibody and at least one peptide linker linking the
CC first and second polypeptide chains. The resulting single chain
CC polypeptide can be used in diagnostics, therapy
CC (in vivo and in vitro), imaging, purifications and biosensors.

XX Sequence 215 AA:

Query Match 96.7%; Score 1084.5; DB 14; Length 215;
Best Local Similarity 96.7%; Pred. No. 3.2e-59;
Matches 208; Conservative 4; Mismatches 2; Indels 1; Gaps 1;

QY 1 ENVLTQSPALMSASPGEGKVTMTCSRASSSVSSYLHWYRQKSGASPKLWYTSNLSAGVP 60
DB 1 envltqspalmsaspgekvtmtcrasssvssylhwfqgksgaspklwystsnlasagvp 60
QY 61 ARFSGSGSTSYSLRTSSVEAEADAATYYCOQYSGY-RTFGGGTKLEIKRADAPTYSIFP 119
DB 61 arfsgsgstsyslrtssveaeadaatyycqysgyplltfgagtkleikradaptysifp 120
QY 120 PSEEDLTSGASVCFPLNNFYPRDINVKWKIDGSEKQNVLSMTDQSKDSTYSMSSTL 179
DB 120 pseqeltsgasvvcflnnfyprdinvwkikdgserqngvlnswtdqskdstysmsstl 180
QY 180 TLTKDEYERHNSYTCGATHTKSTSPYKSFNNRNC 214
DB 181 tltkdeyerhnsytcgatkhtkstspivksfnrnc 215

RESULT 2
R99644
ID R99644 standard; Protein: 215 AA.

XX AC R99644;
XX DT 11-OCT-1996 (first entry)

XX DE Anti-BGH monoclonal antibody light chain.

XX KW Antibody engineering; single polypeptide chain binding molecule;
KW heavy chain; light chain; monoclonal antibody; Mab;
KW bovine growth hormone; BGH; immunoaffinity purification.

XX OS Mus sp.

XX PN US5534621-A.

XX PD 09-JUL-1996.

XX PF 02-SEP-1986; 86US-0902971.

XX PR 19-JAN-1989; 89US-0299617.

XX PR 02-SEP-1986; 86US-0902971.

XX PR 02-SEP-1987; 87US-0092110.

XX PR 25-APR-1990; 90US-0512910.

XX PR 01-APR-1993; 93US-0040440.

XX PR 06-JUN-1995; 95US-0468992.

XX PA (ENZO-) ENZON LABS INC.
XX PI Bird RE, Hardman K, Ladner RC;
XX

DR WPI: 1996-33309/33.
DR N-PSDB; T13734.

PT Immuno-purification using single binding chain molecule including
PT antigen-binding parts of antibody light and heavy chain variable
PT regions connected by a linker - is smaller, stabler and less
XX expansive than complete antibodies

XX Example; Fig 22; 78pp; English.

CC The mature heavy chain (R99643) and mature light chain (R99644) of
CC the mouse anti-bovine growth hormone monoclonal antibody 3C2 can
CC be utilized in novel single chain binding molecules (R99645-48),
CC in which the hypervariable regions from IgG1 3C2 Mab are joined by
CC peptide linkers derived from the Fv regions of an IGA class anti-
CC phosphorylcholine myeloma antibody, MCPC-603. The single chain
CC molecules retain the binding specificity of the light and heavy
CC chains and have the advantages of smaller size, greater stability
CC and reduced cost. They can be used in therapy, diagnostics,
CC imaging, purification and biosensors.

XX Sequence 215 AA:

Query Match 96.3%; Score 1079.5; DB 17; Length 215;
Best Local Similarity 96.3%; Pred. No. 6.5e-59;
Matches 207; Conservative 5; Mismatches 2; Indels 1; Gaps 1;

QY 1 ENVLTQSPALMSASPGEGKVTMTCSRASSSVSSYLHWYRQKSGASPKLWYTSNLSAGVP 60
DB 1 envltqspalmsaspgekvtmtcrasssvssylhwfqgksgaspklwystsnlasagvp 60
QY 61 ARFSGSGSTSYSLRTSSVEAEADAATYYCOQYSGY-RTFGGGTKLEIKRADAPTYSIFP 119
DB 61 arfsgsgstsyslrtssveaeadaatyycqysgyplltfgagtkleikradaptysifp 120
QY 120 PSEEDLTSGASVCFPLNNFYPRDINVKWKIDGSEKQNVLSMTDQSKDSTYSMSSTL 179
DB 120 pseqeltsgasvvcflnnfyprdinvwkikdgserqngvlnswtdqskdstysmsstl 180
QY 180 TLTKDEYERHNSYTCGATHTKSTSPYKSFNNRNC 214
DB 181 tltkdeyerhnsytcgatkhtkstspivksfnrnc 215

RESULT 3
R97377
ID R97377 standard; Protein: 215 AA.

XX AC R97377;

XX DT 13-NOV-1996 (first entry)

XX DE Murine anti-BGH Mab light chain.

XX KW Antibody engineering; monoclonal antibody; Mab; light chain;
KW single chain antibody; immunoassay; bovine growth hormone; BGH.

XX OS Mus musculus.

XX PN US5518889-A.

XX PD 21-MAY-1996.

XX PF 02-SEP-1986; 86US-0902971.

XX PR 19-JAN-1989; 89US-0299617.

XX PR 02-SEP-1987; 87US-0092110.

XX PR 25-APR-1990; 90US-0512910.

XX PR 01-APR-1993; 93US-0040440.

XX PR 06-JUN-1995; 95US-0468988.

PA (ENZO-) ENZON LABS INC.
XX
PI Bird RE, Hardman K, Ladner RC;
XX
DR WPI; 1996-259060/26.
XX N-PSDB; T29057.
XX
PT Immunoassay using single chain antigen binding mol. - as replacement
PT for labelled or immobilised antibody, are less immunogenic, easier
PT to engineer, more stable and less expensive
XX
XX
PS Example 1; Fig 22; 78pp; English.
XX
XX Portions of the heavy chain (R97376) and light chain (R97377) of
CC murine 19G1 anti-bovine growth hormone monoclonal antibody 3C2
CC can be incorporated into novel single polypeptide chain binding
CC molecules (see also W02188-90). These are expressed in host cells
CC using DNA constructs (see also T36460-62) that include heavy and
CC linker moieties. Following expression and refolding, the single
CC chain binding molecules show the binding characteristics of the
CC aggregate of the 2 original heavy and light chains of the variable
CC region of the antibody.
XX
XX Sequence 215 AA;
SQ

Query Match 96.2%; Score 1078.5; DB 17; Length 215;
Best Local Similarity 96.3%; Pred. No. 7.4e-59;
Matches 207; Conservative 4; Mismatches 3; Indels 1; Gaps 1;

QY 1 ENVLTSPTAITSAPGKRYMTCTCASSSVSSHYHWKROKSGAPKIMYSTNLASGVP 60
DB 1 ENVLTSPTAITSAPGKRYMTCTCASSSVSSHYHWKROKSGAPKIMYSTNLASGVP 60
QY ARFSGSGSTSYSLTISSEAEADATYTCOYSGY-RTFEGGCTLETKRDAAPTYSIFP 119
DB 61 ARFSGSGSTSYSLTISSEAEADATYTCOYSGY-RTFEGGCTLETKRDAAPTYSIFP 119
DB 61 ARFSGSGSTSYSLTISSEAEADATYTCOYSGY-RTFEGGCTLETKRDAAPTYSIFP 120
QY 120 PSSEQLTSGASVVCFLNFFPRDINVKWKIDGSEKONGVLSWTDDSKDSTYSMSSTL 179
DB 121 PSSEQLTSGASVVCFLNFFPRDINVKWKIDGSEKONGVLSWTDDSKDSTYSMSSTL 180
QY 180 TLTDEYERHNSYTCETATHTKSTSTPIYKSFNRNCC 214
DB 181 TLTDEYERHNSYTCETATHTKSTSTPIYKSFNRNCC 215

RESULT 4
W06178 ID W06178 standard; Protein; 235 AA.
XX
XX W06178;
AC
DT 17-FEB-1997 (first entry)
XX
DE Murine A5B57 Light chain.
XX
XX ribonuclease; human; bovine; pancreatic; anti-tumour therapy; ADEPT;
KW mustard-ribonuclease; antibody directed enzyme prodng therapy;
KW anti-neoplastic; prodng; reverse polarity; ion pair interaction;
KW reduced immunogenicity; non-selective triggering; primer;
KW polymerase chain reaction; PCR; HP-RNase; Fd; F(ab')2.
XX
XX Synthetic.
XX
XX W09620011-A1.
PN
XX 04-JUL-1996.
PD
XX 21-DEC-1995; 95WO-GB02991.
PF
XX 16-AUG-1995; 95GB-0016810.
PR

PR 23-DEC-1994; 94GB-0026192.
XX
XX (ZENEC) ZENEC LTD.
PA
PI Blakey DC, Boyle FT, Davies DH, Eggelte HJ, Heaton DM;
PI Henman JF, Hennequin LFA, Marsham PR, Rabin BR, Slater AM;
PI Terragona-Fiol A, Taylorson CJ;
XX
XX WPI; 1996-321650/32.
DR N-PSDB; T42508.
XX
XX Two component system for anti-tumour therapy - comprising targeting
PT moiety linked to mutated enzyme which can transform an
PT anti-neoplastic prodng
XX
XX Example 6; Page 119-120; 182pp; English.
XX
XX A two-component system for anti-tumour therapy comprises a targeting
CC moiety linked to a mutated enzyme which can transform an anti-neoplastic
CC prodng. The system is based on antibody directed enzyme prodng therapy
CC (ADEPT) using a non-naturally occurring mutant form of a host enzyme,
CC pref. human pancreatic ribonuclease (HP-RNase), (see T42478-83). The
CC targeting moiety can be an antibody, in partic. murine monoclonal
CC antibody A5B7 (which binds to human carcinoembryonic antigen). A5B7 is
CC suitable for targeting colorectal carcinoma. Fragments, esp. F(ab')2,
CC of the antibody can be conjugated to HP-RNase. A5B7 Fd and L chain
CC fragments were isolated by PCR using cDNA isolated from A5B7 hybridoma
CC cells. The present sequence is that of the murine A5B7 L chain.
XX
XX Sequence 235 AA;
SQ

Query Match 90.1%; Score 1009.5; DB 17; Length 235;
Best Local Similarity 90.2%; Pred. No. 1.3e-54;
Matches 194; Conservative 10; Mismatches 8; Indels 3; Gaps 2;

QY 1 ENVLTSPTAITSAPGKRYMTCTCASSSVSSHYHWKROKSGAPKIMYSTNLASGVP 60
DB 23 QYVLSGSPALISAAPGKRYMTCTCASSSV--LYLHWYQKQKSPKSWIYATSLASGVP 80
QY ARFSGSGSTSYSLTISSEAEADATYTCOYSGY-RTFEGGCTLETKRDAAPTYSIFP 119
DB 61 ARFSGSGSTSYSLTISSEAEADATYTCOYSGY-RTFEGGCTLETKRDAAPTYSIFP 119
DB 81 ARFSGSGSTSYSLTISSEAEADATYTCOYSGY-RTFEGGCTLETKRDAAPTYSIFP 140
QY 120 PSSEQLTSGASVVCFLNFFPRDINVKWKIDGSEKONGVLSWTDDSKDSTYSMSSTL 179
DB 141 PSSEQLTSGASVVCFLNFFPRDINVKWKIDGSEKONGVLSWTDDSKDSTYSMSSTL 200
QY 180 TLTDEYERHNSYTCETATHTKSTSTPIYKSFNRNCC 214
DB 201 TLTDEYERHNSYTCETATHTKSTSTPIYKSFNRNCC 235

RESULT 5
W82746 ID W82746 standard; Protein; 235 AA.
XX
XX W82746;
AC
DT 10-MAY-1999 (first entry)
XX
DE Plasmid pEE14/A5B7/muVkmuck protein.
XX
XX Conjugate; cell targeting; cytotoxic drug; plasmid; fusion protein;
KW prodng-converting enzyme; cell surface antigen; treatment; cancer;
KW inflammation; rheumatoid arthritis; antibody; prodng therapy system.
XX
XX Synthetic.
XX
XX Mus sp.
OS
XX Key Location/Qualifiers
FH 1.22
FT Peptide /label= signal_peptide

xx OS Mus.
xx KM KSI/4; chimeric antibody; light chain variable region;
xx PN EP38767-A.
xx PD 25-APR-1989.
xx PF 18-APR-1989; 89EP-0303814.
xx PR 21-APR-1988; 88US-0184522.
xx PA (ELIL) ELI LILLY AND CO.
xx PI Beavers LS, Bunol TF, Gadski RA, Weigel BJ;
xx DR WPI; 1989-311203/43.
xx DR N-PSDB; N91657.
xx PT Recombinant DNA cpds. producing antibodies - monoclonal and
xx PT chimeric derived from monoclonal antibody KSI/4.
xx PS Claim 1; page 49; 89pp; English.
xx CC The sequence encodes the light chain of Mab KSI/4, used to
xx CC construct mouse/human chimeric antibodies. KSI/4 is a murine antibody
xx CC which binds to surface antigens on adenocarcinoma cells and the use of
xx CC human C regions avoids immunological problems during treatment.
SQ Sequence 213 AA;

Query Match 88.6%; Score 993.5; DB 10; Length 213;
Best Local Similarity 90.6%; Pred. No. 1.1e-53;
Matches 193; Conservative 7; Mismatches 10; Indels 3; Gaps 2;
QY 3 VLTPSPAIMSAPGKXTMTCRASSVSSSYLHWYRKSGASPKIMITSTNLSAGVPAR 62
DB 3 VLTSPAIMSAPGKXTMTCRASSVSSSYLHWYRKSGASPKIMITSTNLSAGVPAR 60
QY 63 FSGSGSGTSYSLTISVFAEDPATYCCOYSGY-RTEGGGTRLEIKRADAPTYSIFPPS 121
DB 61 fsgsgsgtsysllismeaadaalychqsgyptfsggkklktradaapvtvsifpps 120
QY 122 SEQLTSGASVYCFLNFPDINVKWKRIDGSEKONGVLNSWTDDSKDSTYSMSSTLT 181
DB 121 seqltsgasvvcflnfpkdnvkwkldgserqgvlnswtdgskdstysmsstltl 180
QY 182 TKDEYERHNSYTCGATHTKSTSPYKSFNRNDC 214
DB 181 tkdeyerhnsyltceathktspsivksfnrnc 213

RESULT 8
ID R13060
ID R13060 standard; Protein; 235 AA.
AC R13060;
XX 03-OCT-1991 (first entry)
XX Monoclonal antibody OK3T light chain.
XX DE Monoclonal antibody OK3T light chain.
XX KM OK3T; light chain; humanised antibodies; CDR-grafting.
XX OS Mus musculus.
XX FH Key
XX FT Peptide
FT 1..22 Location/Qualifiers
FT /label= signal peptide
FT 23..235
FT Protein
FT /label= light chain

xx PN WO9109967-A.
xx PN WO9109968-A.
xx XX 11-JUL-1991.
xx PF 21-DEC-1990; 90WO-GB02017.
xx PR 21-DEC-1990; 90WO-GB02017.
xx PR 21-DEC-1989; 89GB-0028874.
xx PA (CELL-) CELLTRECH LTD.
xx PI Adair JR, Atwal DS, Emtage JS;
xx DR WPI; 1991-222915/30.
xx DR P-PSDB; R13060.
xx PT New humanised antibodies comprising CDR grafted antibody - with
xx PT heavy and light chains, for use in in vivo therapy and diagnosis
xx PS Disclosure; Fig 1b; 91pp; English.
xx CC The OK3T light chain sequence was deduced from the cDNA sequence
xx CC isolated from a library prepared from OK3T producing cells. The
xx CC library was screened with a probe complementary to a region in the
xx CC mouse kappa constant region. The OK3T sequence was used in CDR-
xx CC grafting experiments to prepare humanised antibodies.
SQ Sequence 235 AA;

Query Match 87.4%; Score 979.5; DB 12; Length 235;
Best Local Similarity 89.2%; Pred. No. 8.4e-53;
Matches 190; Conservative 6; Mismatches 14; Indels 3; Gaps 2;
QY 3 VLTPSPAIMSAPGKXTMTCRASSVSSSYLHWYRKSGASPKIMITSTNLSAGVPAR 62
DB 25 VLTSPAIMSAPGKXTMTCRASSVSSSYLHWYRKSGASPKIMITSTNLSAGVPAR 82
QY 63 FSGSGSGTSYSLTISVFAEDPATYCCOYSGYR-TFEGGTRLEIKRADAPTYSIFPPS 121
DB 83 frsgsgsgtsysllismeaadaalyccqwasnptfsggkklktradaapvtvsifpps 142
QY 122 SEQLTSGASVYCFLNFPDINVKWKRIDGSEKONGVLNSWTDDSKDSTYSMSSTLT 181
DB 143 seqltsgasvvcflnfpkdnvkwkldgserqgvlnswtdgskdstysmsstltl 202
QY 182 TKDEYERHNSYTCGATHTKSTSPYKSFNRNDC 214
DB 203 tkdeyerhnsyltceathktspsivksfnrnc 235

RESULT 9
ID R06477
ID R06477 standard; protein; 195 AA.
AC R06477;
XX 07-JAN-1991 (first entry)
XX Light chain of anti-bovine growth hormone Mab.
XX DE Monoclonal antibody.
XX KM Mus musculus.
XX OS US4946778-A.
XX PN US4946778-A.
XX PD 07-AUG-1990.
XX PF 19-JAN-1989; 89US-0299617.
XX

PR	19-JAN-1989;	89US-0299617.
PR	02-SEP-1986;	86US-0902971.
PR	02-SEP-1987;	87US-0092110.
XX	(GENE-) GENEX CORP.	
PA		
XX		
XX	Ladner RC, Bird RE, Hardman K;	
PI		
XX	WPI, 1990-260350/34.	
DR	N-PSDB; Q05709.	
XX		
PT	Single polypeptide chain binding molecules - having light chain	
PT	variable region of antibody linked by peptide to heavy chain	
PT	variable region.	
XX		
XX	Disclosure: Flg 22; 68pp; English.	
PS		
CC	The MAb is produced by the cell line 3C2. It is an IgG1 with a	
CC	gamma 1 heavy chain and kappa light chain. The sequence was used	
CC	to produce single chain binding molecules comprising the variable	
CC	regions of heavy and light chains linked by a peptide. The	
CC	variable region of the sequence was prepd. by introducing a ClaI	
CC	site and an initiation codon (atcgatg) prior to the first codon of	
CC	the mature sequence and a HindIII site and termination codon	
CC	(taagctt) after codon 109. The plasmid constructed to contain	
CC	this portion was pGX3773. A typical polypeptide construction is:	
CC	Me-[LCVRI(1-41)]-I-I-A-K-A-F-K-N-[HCVR(8-105)]-P-G-S-[LCVR(45-109)].	
CC	This construction is designated TRY40 (see Q05710,R06478).	
CC	See also R06476-84.	
XX		
XX	Sequence 195 AA;	
50		

XX 10-APR-1998; 98FR-0004876.
XX
XX 10-APR-1998; 98FR-0004876.
XX
XX (INMR) BIO MERIEUX.
PA
XX Novelli RA, Monaco S, Pigia N, Berchet C, Mallet F, Cusack S;
PI Chassatng V;
X1
DR WPJ; 1999-593428/51.
DR N-PSDB; Z28804.
XX
PT New peptide ligand specific for p24 of human immune deficiency virus
PT contains hypervariable regions of antibody 13B5, used for diagnosing
PT HIV infection -
XX
XX Claim 2; Page 18-19; 27pp; French.PS
XX The invention relates to a peptide ligand with specific affinity for the
CC p24 protein of human immune deficiency virus-1 (HIV-1) comprising at
CC least one peptide strand corresponding to the N-terminal region of the
CC light and/or heavy chain of the Fab fragment of monoclonal antibody 13B5
CC in which: (1) the light chain includes three hypervariable regions (HVR)
CC at amino acid (aa) positions 24-33, 49-55 and 88-95 of this sequence;
CC and (11) the heavy chain includes three HVR at aa positions 26-35, 49-65
CC and 99-109 of Y44176. The peptide ligands are reagents for detecting p24
CC (by standard immunoassays) in biological samples, specifically for
CC diagnosis of HIV-1 infection or can be used to treat HIV-1 infections.
XX
XX Sequence 208 AA;XQ

	Query Match	86.8%;	Score 973.5;	DB 11;	Length 195;	
	Best Local Similarity	88.8%;	Pred. No. 1.6e-52;			
	Matches 190; Conservative	4;	Mismatches 1;	Indels 19;	Gaps	1
QY	1 ENVTGSPALMSASPGEKVMTTCRASSSVSSSYLHWYRKSGASPEKLMWYSTNLASGP 60					
Dd	1 envltgspalmasapgekvtmctrasssvssylhwfqqksgaspklwlystsnlasyp 60					
QY	61 ARFSGSGSSTYSLSLTISSVEADATYYCCOQYSGYRTFGGKTLEIKRADAPTVSIIPP 120					
Dd	61 arfsgsgstyslsltlssveadatyccooqygyrftfggktleikradaptvsiifpp 101					
QY	121 SSEDLTSGGSAYVCFLNFPDPDINVKWKIDGSEKONGVLNSWTDDSKDSTYSMSSTLT 180					
Dd	102 sseqltsggsayvcflnfpdkdinvwkwidserngylvlnswtdqskdstysmsstlm 161					
QY	181 LTKDEYERHNSYTCEATHKTSPTPIKSFNRNC 214					
Dd	162 ltkdeyerhnsytceathkstpslrvksinrnec 195					
RESULT	10					
ID	Y44175					
	Y44175 standard; Protein; 208 AA.					
XX	XX					
AC	Y44175;					
XX	XX					
DT	01-FEB-2000 (first entry)					
XX	XX					
DE	Mab FabI3B5 light chain protein sequence.					
XX	XX					
KM	Peptide ligand; affinity; p24; human immune deficiency virus-1; HIV-1;					
KW	light chain; heavy chain; Fab; monoclonal antibody; hypervariable region.					
XX	infection.					
OS	Mus sp.					
XX	XX					
PN	FR277285-A1.					
XX	XX					
DD	15-OCT-1999					

Query Match	84.7%	Score 950	DB 20	Length 208
Best Local Similarity	88.1%	Pred. No. 4.6e-51		
Matches 185	Conservative	9	Mismatches 14	Indels 2
				Gaps 1
QY	1	ENVLTQSPAINMSASPEGEVMTWCRASSVSSTSLHMYRQKSGASPKLWITYSTNLSAGVP	60	
Db	1	elvtlsgpaicaaslgdqrvltlctssassv--symhygqksgtspkpwlyelsklasgvp	58	
QY	61	ARFSGSGGTSYLSTLTSSVEAEADAAITTYTCQOYSGYRTFEGGKLEIKRADAAPVSIIPP	120	
Db	59	arfsgsggtsysltlssimeeadaalygcqnygtftfsgkgleikradaapvtslfpp	118	
QY	121	SSEQLTSGGASVYCCVLPNFPDPIVWKKIDGSEKQNYGLNWTODSKDSTIYSSMSTLT	180	
Db	119	sseqltsggaasvccflnftypkdlnvkkldgserqnyglnswtdqskdstysmstlt	178	
QY	181	LTKDEYERHNSYTCGATHTKSTSPVKKSPN	210	
Db	179	ltkdeyerhnsytcgatkstspivkspn	208	
RESULT 11				
W83042				
ID	W83042	standard	Protein	238 AA
XX	AC			
XX	W83042			
XX	DT	15-MAR-1999	(first entry)	
XX	DE	Anti-Fas MAb HFE7A	light chain	
KM	HFE7A	monoclonal antibody	mouse	Fas
KM	apoptosis	HFE7A	autoimmune disease	Hashimoto's disease
KM	Sjogren syndrome	pernicious anaemia	graft versus host disease	
KM	steroidemia	Goodpasture syndrome	Crohn's disease	sterility
KM	rheumatoid arthritis	autoimmune haemolytic anaemia		
KM	myasthenia gravis	multiple sclerosis	Basedow's disease	
KM	thrombopenia purpura	insulin-dependent diabetes	allergy	
KM	atopy	arteriosclerosis	myocarditis	cardiomyopathy

SQ Sequence 238 AA:
 Query Match 81.3%; Score 911; DB 21; Length 238;
 Best Local Similarity 81.0%; Pred. No. 1,2e-48;
 Matches 175; Conservative 16; Mismatches 21; Indels 4; Gaps 2;
 QY 3 VLNQSPAIMSASPERKVTMTCRASSV---SSSYLMHYRQKSGASPKLWITYSTNLSAGV 59
 Db 23 vltqspaslaavslgqrattlsckasgsvdydgdsymmyqkqpgpklllyaaasnlsgsl 82
 QY 60 PARFSSGSGSTSLTISSEADATYYCOQYS-GYRFGGCTKEIKRADAPVSTF 118
 Db 83 pafisgsgstldtlnlhpveedaatyccqgsnedprtfgggtkikrdaapvtvsif 142
 QY 119 PPSEDLTSGASVGFELNNFYPRDINVKWKIDGSRONGVLNSWPTDQSKDSTYSMSST 178
 Db 143 ppsedltsqgavvcflnfyprkdlvkvkldgserqgvlnswtdqskdsktysmsst 202
 QY 179 LTLTKDEYERHNSYTCGATHKSTSPIVKSFNNEC 214
 Db 203 ltltkdeyerhnsytcgathkstspivksfnnecc 238

RESULT 13
 W90898 ID W90898 standard; Protein; 238 AA.

W90898:

08-AUG-2000 (first entry)

Murine anti-Fas antibody HFE7A light chain protein.

KW Fas; antibody; murine; anti-inflammatory; anti-anemic; antidiabetic;
 KW anti-allergic; anti-arthritis; antiviral; immunomodulatory; cardiac;
 KW dermatological; immunosuppressive; chylomicric; antirheumatic; anti-Fas;
 KW nephrotropic; antileukemia; neuroprotective; antileukemia; antileukemia;
 KW hepatocellular; humanized; apoptosis; systemic lupus erythematosus; HFE7A;
 KW Hashimoto's disease; rheumatoid arthritis; graft versus host disease;
 KW Sjogren's syndrome; anemia; Addison's disease; scleroderma; sterility;
 KW Goodpasture syndrome; Crohn's disease; sterility; myasthenia gravis;
 KW multiple sclerosis; Basedow's disease; thrombopenia purpura; allergy;
 KW insulin dependent diabetes mellitus; arteriosclerosis; myocarditis;
 KW cardiomyopathy; glomerulonephritis; hepatitis; transplant rejection.

OS Mus musculus.

PN EP990663-A2.

PD 05-APR-2000.

PF 29-SEP-1999; 99EP-0307711.

PR 30-SEP-1998; 98JP-0276881.

PR 30-SEP-1998; 98JP-0276882.

PA (SANY) SANKYO CO LTD.

PI Serizawa N, Haryama H, Nakahara K, Tamaki I, Takahashi T;

DR WPI; 2000-258930/23.

DR N-PSDB; A11547.

PT New humanized anti-Fas antibody, useful for treating or preventing e.g.

PT inflammatory or autoimmune disease, induces apoptosis selectively in

PS cells with abnormal Fas-Fas ligand systems -.

CC Example reference 4; Page 104; 263pp; English.

CC This invention describes a novel humanized anti-Fas antibody-like

CC molecule (I) that, induces apoptosis in cells with an abnormal Fas/Fas

CC ligand system, by binding to Fas on the cell surface, and prevents

CC apoptosis in cells with a normal system, by inhibiting binding between
 CC Fas and its ligand. The products of the invention have anti-inflammatory,
 CC anti-anemic, antidiabetic, anti-allergic, anti-arthritis, antiviral,
 CC immunomodulatory, dermatological, immunosuppressive, thyromimetic,
 CC antirheumatic, nephrotropic, antileukemia, neuroprotective,
 CC antileukemia, antileukemia, antileukemia, antileukemia, antileukemia,
 CC inhibition of binding to cell surface Fas or inhibit it by competitive
 CC inhibition of ligand binding. (I) are used to treat and/or prevent
 CC diseases associated with the Fas/Fas ligand system, especially systemic
 CC lupus erythematosus, Hashimoto disease, rheumatoid arthritis, graft
 CC versus host disease, Sjogren's syndrome, pernicious or hypoplastic
 CC anemia, Addison's disease, scleroderma, Goodpasture syndrome, Crohn's
 CC disease, autoimmune hemolytic anemia, sterility, myasthenia gravis,
 CC multiple sclerosis, Basedow's disease, thrombopenia purpura, insulin
 CC dependent diabetes mellitus, allergy, arteriosclerosis, myocarditis,
 CC cardiomyopathy, glomerulonephritis, hepatitis (fulminant, chronic, viral
 CC (B, C or D) or alcoholic), and transplant rejection. (I) selectively
 CC inhibit apoptosis in normal cells but selectively induce it in abnormal
 CC cells. They bind to both human and murine Fas, so can be evaluated in
 CC murine disease models. (I) act on the active site of Fas, i.e. they mimic
 CC the native ligand, do not induce liver disease, and have reduced risk of
 CC inducing a human anti-murine antibody response. This sequence represents
 CC a murine anti-Fas monoclonal antibody HFE7A light chain described in the
 CC method of the invention.

SQ Sequence 238 AA:

Query Match 81.3%; Score 911; DB 21; Length 238;
 Best Local Similarity 81.0%; Pred. No. 1,2e-48;
 Matches 175; Conservative 16; Mismatches 21; Indels 4; Gaps 2;

QY 3 VLNQSPAIMSASPERKVTMTCRASSV---SSSYLMHYRQKSGASPKLWITYSTNLSAGV 59
 Db 23 vltqspaslaavslgqrattlsckasgsvdydgdsymmyqkqpgpklllyaaasnlsgsl 82
 QY 60 PARFSSGSGSTSLTISSEADATYYCOQYS-GYRFGGCTKEIKRADAPVSTF 118
 Db 83 pafisgsgstldtlnlhpveedaatyccqgsnedprtfgggtkikrdaapvtvsif 142
 QY 119 PPSEDLTSGASVGFELNNFYPRDINVKWKIDGSRONGVLNSWPTDQSKDSTYSMSST 178
 Db 143 ppsedltsqgavvcflnfyprkdlvkvkldgserqgvlnswtdqskdsktysmsst 202
 QY 179 LTLTKDEYERHNSYTCGATHKSTSPIVKSFNNEC 214
 Db 203 ltltkdeyerhnsytcgathkstspivksfnnecc 238

RESULT 14

R76086 ID R76086 standard; Peptide; 219 AA.

AC R76086:

DT 21-NOV-1995 (first entry)

DE MAB 55.1 light chain.

KW Antigen binding structure; complementarity determining region; CDR;

KW CA5.1; colorectal cancer; tumor-associated antigen; hybridoma;

KW monoclonal antibody; MAB; immunotherapy; therapy; diagnosis;

KW transgenic animal; transgenic plant; antibody engineering;

KW humanized antibody; immunotoxin.

OS Mus sp.

PN W09515382-A.

PD 08-JUN-1995.

PF 29-NOV-1994; 94WO-GB02610.

